Sign in Subscribe
COVID-19

BNT162b2 Vaccine Shows Promising Results in Lung Cancer Patients

Strategic Insights

— 1 min read

Lung cancer patients undergoing anticancer treatment who received the BNT162b2 mRNA vaccine exhibited a significant increase in antibody titers against the acute respiratory syndrome coronavirus-2 (SARS-CoV-2) spike protein S1 subunit receptor-binding domain. However, the immunogenicity in these patients was found to be inadequate compared to non-cancer patients. The study, published on medrxiv.org, assessed the safety and immunogenicity of the BNT162b2 vaccine in a cohort of 55 lung cancer patients and 38 non-cancer patients.

Key Takeaways:

  • The BNT162b2 mRNA vaccine induced a significant increase in antibody titers against SARS-CoV-2 spike protein S1 subunit receptor-binding domain in lung cancer patients undergoing anticancer treatment.
  • The geometric mean antibody titer in lung cancer patients was 30 AU/mL, which was significantly lower than that in non-cancer patients (121 AU/mL, p < 0.001).
  • The study demonstrated acceptable safety of the BNT162b2 vaccine in lung cancer patients undergoing anticancer treatment.
  • Immunogenicity in lung cancer patients was found to be inadequate compared to non-cancer patients.
  • The study highlights the importance of further research into the optimal vaccination strategies for cancer patients.

Statistics:

  • 55 lung cancer patients and 38 non-cancer patients were included in the immunogenicity analysis.
  • The geometric mean antibody titer in lung cancer patients was 30 AU/mL.
  • The geometric mean antibody titer in non-cancer patients was 121 AU/mL.
  • p < 0.001 for the comparison between lung cancer patients and non-cancer patients.

Sources:

  • medrxiv.org/content/10.1101/2022.06.23.22276536v1

Read more